Search | Clinical Trials Finder

Conditions: Night Eating Syndrome
Interventions: Escitalopram, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: St Louis, Missouri • Durham, North Carolina

Conditions: Depression
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Major Depressive Disorder
Interventions: Not listed
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 10
States / cities: Los Angeles, California • San Diego, California • Torrance, California + 6 more

Conditions: MDD, Citalopram, Major Depressive Disorder
Interventions: citalopram; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Major Depressive Disorder, Anxiety, Comorbidity
Interventions: Vilazodone, Citalopram; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 50 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder
Interventions: Placebo, intermittent theta burst stimulation, intravenous citalopram hydrochloride (CIT), continuous theta burst stimulation; Drug · Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Depressive Disorder
Interventions: Escitalopram; Drug
Lead sponsor: Pharmacology Research Institute; Other
Eligibility: 18 Years to 80 Years
Timeline: Started 2005
U.S. locations: 4
States / cities: Los Alamitos, California • Newport Beach, California • Northridge, California + 1 more

Conditions: Autism Spectrum Disorder
Interventions: Escitalopram 10mg, Placebo; Drug
Lead sponsor: Kathryn Unruh; Other
Eligibility: 12 Years to 17 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Major Depressive Disorder (MDD)
Interventions: Escitalopram, Aripiprazole, Blinded capsule; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 24
States / cities: Cerritos, California • Costa Mesa, California • Irvine, California + 21 more

Conditions: Generalized Anxiety Disorder
Interventions: Cognitive Behavioral Therapy, escitalopram; Behavioral · Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Depressive Disorder
Interventions: saredutant (SR48968), placebo, escitalopram; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 60 Years to 64 Years
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Major Depressive Disorder
Interventions: Placebo, Escitalopram, JNJ-18038683; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 26
States / cities: Little Rock, Arkansas • Beverly Hills, California • Glendale, California + 23 more

Conditions: Amyloid Beta Protein
Interventions: Escitalopram 20mg for 2 weeks, Escitalopram 20mg for 8 weeks, Escitalopram 30mg for 8 weeks, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 60 Years to 85 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: St Louis, Missouri • Philadelphia, Pennsylvania

Conditions: Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions: Not listed
Lead sponsor: Genelex Corporation; Industry
Eligibility: 65 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more

Conditions: Alzheimer Disease
Interventions: Escitalopram Pill, Venlafaxine Pill, Placebo Oral Tablet; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 60 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder, Mild Neurocognitive Disorder, HIV
Interventions: Pramipexole ER, Escitalopram; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 25
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more

Conditions: Major Depressive Disorder, Insomnia
Interventions: escitalopram and eszopiclone, Escitalopram, eszopiclone, and placebo, Escitalopram; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 64 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pancreatic Ductal Adenocarcinoma, Periampullary Cancer
Interventions: Escitalopram, Placebo; Drug · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Depression, Depressive Disorder, Depressive Disorder, Major
Interventions: Desvenlafaxine succinate sustained-release (DVS SR), Escitalopram; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 595 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 52
States / cities: Peoria, Arizona • Pasadena, California • San Diego, California + 46 more

Conditions: Major Depressive Disorder
Interventions: Escitalopram; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 18
States / cities: Phoenix, Arizona • Boulder, Colorado • Denver, Colorado + 15 more

Conditions: Autistic Disorder
Interventions: citalopram hydrobromide, placebo; Drug · Other
Lead sponsor: Boston University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 6
States / cities: Los Angeles, California • New Haven, Connecticut • Lebanon, New Hampshire + 3 more

Conditions: Major Depressive Disorder, Alcohol Abuse, Alcohol Dependence
Interventions: acamprosate, escitalopram, Medical management, Placebo; Drug · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 64 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Autism
Interventions: Behavioral Assessment; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 5 Years to 18 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: OCD
Interventions: escitalopram, Placebo ( sugar pill); Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Escitalopram Treatment of Night Eating Syndrome

p11 Protein Levels in Patients With Major Depressive Disorder Treated With Citalopram

EEG Biomarkers for Predicting Response to Antidepressant Therapy

Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression

The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives

Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)

Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder

Neuroimaging of Escitalopram in Autism Spectrum Disorder

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD)

An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder

A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression

Escitalopram Effects on CSF Amyloid Beta

YouScript IMPACT Registry

A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol

Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

Brain Mechanisms and Targeting Insomnia in Major Depression

Escitalopram to Placebo in Patients With Localized Pancreatic Cancer

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder

Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)

Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism

Use of Functional Behavioral Assessments to Evaluate Stereotypy and Repetitive Behaviors in a Double-blind, Placebo Controlled Trials of Various Medications Used to Treat Children With Autism.

Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder